Medtronic’s DBS therapy for treatment-resistant epilepsy has produced long-lasting improvements in quality of life after 5 years, according to detailed results from a pivotal clinical trial.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1BaGPsz
Cap comentari:
Publica un comentari a l'entrada